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Abstract 
Background. Malnutrition is common in patients treated with peritoneal dialysis (PD). Previous studies have 
disclosed disturbances in the hormonal axes regulating appetite in these patients. The effect of newer 
biocompatible PD solutions on these disorders is undetermined. 
Methods. Using a crossover randomized design, 21 patients stable on PD underwent 5 weeks of therapy with 
each of classic glucose degradation product (GDP)-rich lactate-buffered PD solutions (L) and newer low-
GDP bicarbonate–lactate-buffered PD solutions (BL). At the end of each phase, we scrutinized patients for 
adequacy markers, peritoneal transport (peritoneal equilibration test with 3.86% glucose-based solutions), 
general biochemical markers and, more specifically, cytokines, adipokines (leptin and adiponectin) and 
selected gastrointestinal peptides which regulate appetite in the short term [ghrelin, peptide YY, 
cholecystokinin, glucagon-like peptide 1 (GLP1)]. For plasma GLP1 levels, we analysed a group of healthy, 
sex-, age- and body mass index-matched controls. 
Results. Use of BL solutions was associated with higher plasma levels of acylated (but not total) ghrelin 
(median 243 BL versus 141 pg/mL L, P = 0.05), adiponectin (median 20.2 BL versus 17.6 mcg/mL L, P = 
0.008) and growth hormone (median 1.8 BL versus 1.0 ng/mL L, P = 0.013), without significant differences 
for the other cytokines, leptin or gut peptides scrutinized. We did not observe significant differences between 
L and BL solutions concerning estimations of adequacy, peritoneal transport or general biochemical markers. 
Conclusions. Use of GDP-free, neutral-pH, bicarbonate–lactate-buffered PD solutions is associated with 
higher plasma levels of acylated ghrelin and adiponectin than classic solutions. These findings may contribute 
to explaining improved appetite scores and overall survival rates reported with the use of so-called 
biocompatible PD solutions. 
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Introduction 
During the last decade, traditional glucose-based, lactate-buffered, glucose degradation product 
(GDP)-rich peritoneal dialysis (PD) solutions have been progressively, yet not completely 
substituted by newer, seemingly more biocompatible solutions, with a low content in GDP and in 
which lactate has been totally or partially replaced by bicarbonate as a buffer. Many in vitro and ex 
vivo studies have shown the beneficial effects of these solutions for the preservation of the 
integrity of the peritoneal membrane [1 , 2 , 3] and peritoneal membrane defense mechanisms [4]. 
On the other side, evidence linking these solutions to systemic benefits and better clinical 
outcomes, including preservation of residual renal function (RRF) [5 , 6 , 7], peritonitis rates [2 , 
5], improved peritoneal membrane longevity [5] or patient survival [8], are encouraging, but more 
controversial.  
 
Malnutrition is frequent in patients undergoing renal replacement therapy, bearing a significant 
impact on their outcomes. The genesis of malnutrition in this setting is complex, but anorexia is 
undoubtedly a main pathogenic factor [9]. It has been suggested that patients treated with PD may 
be particularly prone to anorexia [10], due both to the caloric contribution of glucose-infused 
intraperitoneally and to abdominal fullness favoured by an elevated intraperitoneal pressure.  
 
PD solutions are able to modify the secretion patterns and plasma levels of adipokines and 
gastrointestinal peptides which regulate cycles of hunger and satiety [11 , 12 , 13]. However, there 
is a remarkable paucity of information about the specific effects of so-called biocompatible PD 
solutions on the secretion patterns and plasma levels of appetite-regulatory hormones. We have 
undertaken a randomized crossover study, with the main objective of comparing the effect of 
classic lactate-based and new, neutral-pH, bicarbonate–lactate-based GDP-free PD solutions on 
plasma levels of adipokines and selected gastrointestinal appetite-regulatory peptides.  
Population and methods 
General design 
Following a prospective crossover design, patients stable on chronic PD therapy underwent 
two consecutive periods of 5 weeks using either classic, lactate-buffered, GDP-rich (thereafter 
designed as L) or bicarbonate–lactate-buffered, neutral-pH, low-GDP PD solutions (designed as 
BL) in a randomized order. The PD prescription was otherwise kept essentially invariable during 
the whole study span. At the end of each period, we scrutinized patients for adequacy markers, 
peritoneal transport (standard Peritoneal Equilibration Test PET using 3,86% glucose-based 
dialysate) and selected appetite-regulatory hormones, including adipokines (leptin, adiponectin) 
and gut peptides: ghrelin, peptide YY, cholecystokinin and glucagon-like peptide 1 (GLP-1). 
 
The study protocol fulfilled the requirements of the ethical committee of our centre, and 
written informed consent was obtained from all patients. 
Subjects 
Patients were selected from our population undergoing chronic PD therapy, after applying the 
following exclusion criteria: age <18 or >85 years, chronic PD for <2 months, significant clinical 
events (including peritonitis) during the previous 3 months and unwillingness or inability to 
cooperate. Twenty-nine patients were eligible, but we excluded five due to refusal to participate ( n 
= 1) or nonmedical reasons ( n = 4). Thus, 24 patients were randomized, but 3 could not complete 
the study due to renal transplantation ( n = 2) or adverse event ( n = 1, pulmonary infection). The 
study flow diagramme is depicted in Figure 1 . The main characteristics of the final study group 
are presented in Table 1 . 
  
 
 
Fig. 1. Study flow chart. 
Table 1. Main characteristics of patients in the study 
  
Age (years)  57 (21–84) 
Sex (males/females) (%)  16/5 (76.2/23.8) 
Kidney disease  
 
  Glomerular  3 
  Interstitial  3 
  Vascular  4 
  Cystic  3 
  Diabetic nephropathy  5 
  Other/unknown  3 
Diabetes (%)  7 (33.3%) 
Modality of PD (CAPD/automated PD) (%)  10/11 (47.6/52.4) 
Icodextrin (%)  15 (71.4) 
Aminoacid-based solutions (%)  9 (42.9) 
Body mass index (kg/m 2 )   26.1 (19.8–36.4) 
Obese patients (>30 kg/m 2 ) (%)   3 (14.3) 
Time on PD at the start of the study (months)  26 (5–74) 
Patients with previous peritonitis (%)  10 (47.6) 
Main drug therapies (%)  
 
  Furosemide  10 (47.6) 
  Calcium antagonists  9 (42.9) 
  ACEI-ARA  13 (61.9) 
  Statins  13 (61.9) 
  Antiplatelet drugs  6 (28.6) 
  Insulin  5 (23.8) 
  
Study protocol 
Before the start of the study, all patients were treated with conventional L solutions (Dianeal; 
Baxter, Deerfield, IL). We randomized them to either 5 weeks on the same regime under tight 
prescription control or switch to BL solutions (Physioneal Clear Flex; Baxter). At the end of this 
period, blood and dialysate samples were collected for adequacy (Kt/V, creatinine clearance, RRF) 
and for the scrutiny of the selected biochemical, inflammation and hormonal variables (see below). 
All blood samples were retrieved after an overnight fast; the usual PD prescription was maintained 
during this overnight period. A standard 4-h 3.86% PET was also performed, using the type of 
solution (either BL or L) of the corresponding study period. Patients were then switched to the 
alternative PD solution, keeping the remaining prescription parameters as constant as possible. 
Five weeks later, adequacy, blood sample collection and a 3.86% PET were repeated. During both 
study periods, patients recorded daily at home their blood pressure, body weight and ultrafiltration 
rates (difference between infusion and drainage bags for manual exchanges), as also any changes 
to the PD regime. 
 
Blood biochemical estimations included urea, creatinine, glucose, sodium, potassium, calcium, 
phosphate, venous pH, bicarbonate, albumin, cholesterol and triglycerides. Markers of 
inflammation and endothelial dysfunction included C-reactive protein (CRP), interleukin 6 (IL-6) 
and 10 (IL-10), Intercellullar adhesion molecule-1, total homocysteine, transforming growth factor 
β1 (TGF-β1) and vascular endothelial growth factor (VEGF). We also scrutinized adipokines, 
hormones and appetite-regulatory peptides, including leptin, adiponectin, insulin, GLP1(7–36), 
growth hormone (GH), ghrelin (total and acylated), PYY (1–36 and 3–36) and cholecystokinin. Given 
the paucity of previous information on this hormone, in the case of GLP-1, we also present values 
estimated in a group of age 48, sex and BMI-matched controls, recruited from a pool of healthy 
individuals available to the Endocrinology Unit of our center.  
 
Total Kt/V creatinine clearance and normalized protein nitrogen appearance were estimated 
with the Adequest® software (Baxter). Twenty-four- hour peritoneal glucose absorption was 
calculated by simple mass balance. Ultrafiltration during 3.86% PET was estimated from the 
difference of weight of the dialysate bag before infusion and after final drainage. RRF (Glomerular 
filtration rate (GFR)] was estimated as the mean of urea and creatinine clearances, after 24-h urine 
collections. 
Sample management and laboratory methods 
Blood samples for biochemical determinations were processed immediately. Those destinated 
to estimations of hormones, gut peptides, adipokines and inflammatory markers were immediately 
centrifuged, separated and frozen at −80°C. Samples for determination of plasma ghrelin levels 
were specifically retrieved to chilled tubes containing aprotinin and EDTA-Na and then 
immediately centrifuged at 4°C, separated to aliquots and frozen at −80°C. 
 
We used an autoanalyser for all standard biochemical determinations. CRP was estimated 
using a high-sensitivity immunoturbidimetric assay (Roche, Mannheim, Germany). IL-6, IL-10, 
TGF-β1 and VEGF were estimated using ELISA assays (R&D Systems, Minneapolis, MN). Total 
homocysteine levels were estimated by fluorescence polarization immunoanalysis (Imx; Abbott 
Lab., Abbott Park, IL). For estimation of the scrutinized hormones, we used the following specific 
commercial radioimmunoassays: PYY (1–36) and PYY (3–36) (Linco, St. Charles, MO), total ghrelin 
(Phoenix Pharmaceuticals, Belmont, CA), acylated ghrelin (Linco), cholecystokinin (Alpro, 
Windham, NH), GH (Nichols Inst. Diagnostics, San Juan Capistrano), leptin (Mediagnost, 
Tübingen, Germany), adiponectin (Millipore, Billerica, MA), GLP-1 (Millipore) and insulin (CIS 
Bio International, Cedex, France).  
  
Statistics 
Numerical variables are presented as median values (range), unless otherwise stated. For 
comparisons between the study periods, we used Student’s t -test (paired) and Wilcoxon’s test. 
Comparisons between subgroups of patients were based on Fisher’s (categorical) and Mann–
Whitney U- (numerical) tests. Numerical correlations were analysed using the Spearman’s 
correlation test. Unless otherwise stated, the results reported for secondary correlations correspond 
to the BL period. P-values ≤0.05 were considered to be significant. We used the SPSS 17.0 
software for statistical analysis.  
Results 
All patients were able to maintain stable PD regimes during the whole study period. There 
were no differences in the general biochemical profile during the study period, except for a 
nonsignificant trend to higher blood bicarbonate levels during the BL phase ( Table 2 ). We also 
did not observe any significant differences in the adequacy or PET-related estimations between the 
study periods ( Table 3 ).  
Table 2. Main laboratory variables a 
  Bicarbonate–lactate Lactate P 
    
Urea (mg/dL)  149 (101–251) 152 (108–274) NS 
Creatinine (mg/dL)  7.1 (3.7–14.9) 7.3 (3.6–16.8) NS 
Sodium (mM/L)  139 (131–143) 137 (133–144) NS 
Potassium (mM/L)  4.8 (3.7–6.0) 4.9 (3.7–6.2) NS 
Blood pH (venous)  7.32 (7.23–7.38) 7.31 (7.25–7.41) NS 
Bicarbonate (mM/L)  22.2 (16.1–25.4) 21.7 (17.1–30.7) 0.07 
Calcium (mg/dL)  9.1 (8.1–10.4) 9.1 (8.2–10.3) NS 
Phosphate (mg/dL)  5.1 (3.2–6.7) 5.2 (3.7–7.1) NS 
Glycemia (mg/dL)  93 (80–221) 91 (73–250) NS 
Albumin (g/L)  37 (32–47) 38 (32–44) NS 
Cholesterol (mg/dL)  161 (93–234) 176 (90–216) NS 
Triglycerides (mg/dL)  117 (53–269) 123 (51–455) NS 
Homocysteine (μM/L)  26 (15–173) 26 (16–139) NS 
ICAM-1 (ng/mL)  330 (99–513) 313 (140–544) NS 
Interleukin 6 (pg/mL)  7 (3–21) 6 (3–16) NS 
Interleukin 10 (pg/mL)  0.8 (0.1–7.2) 1.5 (0.1–11.2) NS 
CRP (mg/dL)  4.1 (1.0–41) 3.0 (1.0–11.2) NS 
TGF-β1 (ng/mL)  7 (0.15) 7 (0.12) NS 
VEGF (pg/mL)  107 (22–400) 100 (5–455) NS 
    
 
Figures denote median values (range). Comparisons by Student’s t -test (paired) and 
Wilcoxon’s test.  
a ICAM, Intercellullar adhesion molecule-1.
Table 3. Peritoneal transport and adequacy markers a 
  Bicarbonate–lactate Lactate P 
    
Body weight (kg)  71.5 (48–105.5) 71.5 (49–105) NS 
Diuresis (mL/day)  1100 (0–3500) 1400 (0–2700) NS 
GFR (mL/min)  5.0 (0–11.5) 6.4 (0–10.8) 0.07 
Peritoneal Kt/V  1.14 (0.97–2.20) 1.06 (0.91–2.60) NS 
Peritoneal creatinine clearance (L/week/1.73 m 2 )   38.9 (22.1–84.3) 42.0 (22.4–85.4) NS 
Peritoneal glucose load (g/day)  79.6 (27.2–178.8) 79.6 (27.2–178.8) NS 
Peritoneal glucose absorption (g/day)  35.4 (14.4–66.7) 36.4 (12.2–71.1) NS 
nPNA (g/kg/day)  1.12 (0.68–1.91) 1.11 (0.64–1.70) NS 
Peritoneal protein excretion (g/day)  5.0 (2.7–10.4) 4.6 (2.6–9.1) NS 
Daily ultrafiltration (L)  720 (200–2350) 720 (200–2400) NS 
Peritoneal sodium removal (mM/day)  54 [(−37) to 184] 64 [(−36) to 184] NS 
Systolic blood pressure (mmHg)  131 (99–160) 130 (86–155) NS 
Diastolic blood pressure (mmHg)  79 (61–101) 77 (45–103) NS 
D/P 240′ creatinine (PET)  0.71 (0.49–1.02) 0.71 (0.45–0.93) NS 
Ultrafiltration during PET (mL)  550 (50–900) 650 (0–1450) NS 
Sodium dip 60’ (mM/L) (PET)  3 [(−1) to 14] 6 (2–13) 0.09 
    
 
Figures denote median values (range). Comparisons by Student’s t -test (paired) and Wilcoxon’s test.  
a nPNA, Normalized protein nitrogen appearance. 
Table 4 shows the main comparisons between the levels of the selected adipokines, hormones 
and appetite-regulatory peptides. Interestingly, levels of GH (mean difference 1.32 ng/mL, i 0.51, 
P = 0.01), acylated (but not total) ghrelin (mean difference 64.5 pg/mL, SEM 29.7, P = 0.05) ( 
Figure 2a ) and adiponectin (mean difference 1.90 mcg/mL, SEM 1.06, P = 0.008) ( Figure 2b ) 
were significantly higher after 5 weeks of treatment with BL solutions. Plasma levels of GLP1 7–36 
did not differ between the study phases ( Table 4 ) and were not significantly different from those 
observed in normal controls (median 13.2 pM/L, range 1.1–38.6). 
Table 4. Hormones, adipokines and appetite-regulatory peptides 
  Bicarbonate–lactate Lactate P 
    
Insulin (mcU/mL)  27.3 (8.7–71.9) 28.8 (12.2–87.8) NS 
GLP1 7–36 (pM/L)   11.8 (0.9–22.4) 10.5 (1.1–20.1) NS 
GH (ng/mL)  1.8 (0.1–7.6) 1.0 (0.1–5.7) 0.013 
Adiponectin (mcg/mL)  20.2 (8.9–42.9) 17.6 (6.7–40.3) 0.008 
Leptin (ng/mL)  13.6 (2.8–297.0) 18.7 (3.7–349.0) NS 
Ghrelin, total (pg/mL)  1895 (656–4264) 2010 (745–4447) NS 
Ghrelin, acylated (pg/mL)  243 (45–482) 141 (48–586) 0.05 
Ratio acylated/total ghrelin  0.12 (0.03–0.42) 0.08 (0.02–0.29) 0.09 
PYY 1,36 (pg/mL)   461 (307–1024) 482 (245–949) NS 
PYY 3,36 (pg/mL)   178 (104–454) 170 (77–401) NS 
Cholecystokinin (pM/L)  0.29 (0.09–4.60) 0.34 (0.08–4.55) NS 
    
 
Figures denote median values (range). Comparisons by Student’s t (paired) and Wilcoxon’s tests. 
 
 
 
 
( a ) Plasma levels of acylated ghrelin (pg/mL) after 5 weeks of therapy with GDP-rich 
lactate-buffered solutions and low-GDP bicarbonate–lactate-buffered solutions. ( b ) 
Plasma levels of adiponectin (mcg/mL) after 5 weeks of therapy with GDP-rich lactate-
buffered solutions and low-GDP bicarbonate–lactate-buffered solutions. 
In general, observed blood levels of cytokines, adipokines and gut peptides were tightly 
correlated in both periods (Spearman’s correlation coefficients > 0.80), with the remarkable 
exceptions of insulin ( r = 0.36, P = 0.10) and GLP-1 ( r = 0.35, P = 0.23). Plasma levels of PYY 
1–36 and PYY 3–36 ran tightly correlated ( r = 0.81, P = 0.002), while plasma levels of total and 
acylated ghrelin did not ( r = 0.27, Not significant). Plasma GH levels were correlated with 
adiponectin ( r = 0.61, P = 0.007) and acylated ghrelin ( r = 0.46, P = 0,04). As refers to other 
variables, age correlated inversely with blood levels of total ghrelin ( r = −0.62, P = 0.003), PYY 
1–36 ( r = −0.49, P = 0.04) and PYY 3–36 ( r = −0.56, P = 0.008) and directly with IL-6 ( r = 0.51, P 
= 0.02). On the other hand, GFR showed an inverse correlation with blood levels of PYY 1–36 ( r = 
−0.58, P = 0.006), PYY 3–36 ( r = −0.52, P = 0.015) and IL-6 ( r = −0.65, P = 0.009) and directly 
with GH ( r = 0.58, P = 0.008) and IL-10 ( r = 0.77, P = 0.002). As expected, leptin levels 
correlated with body mass index ( R = 0.65, P = 0.002) and tended to be higher in women (median 
21.1 versus 14.8 ng/mL, P = 0.07).  
Discussion 
The general results of our study agree for the most part with previous short- and mid-term 
reports comparing L and BL solutions. Both types of solution yielded similar results as refers to 
adequacy, general biochemical and PET-related markers ( Tables 2 and 3 ). PET results disclosed a 
nonsignificant trend to lower Ultrafiltration (UF) and less sodium dip at 60 min with BL than with 
L solutions ( Table 3 ). The compared UF rates yielded by L and BL solutions are a matter of 
controversy. The current view suggests that, for reasons which are not totally clear, BL solutions 
may yield marginally lower UF in the short-term [5 , 7 , 13 , 14 , 15], while a better preservation of 
peritoneal integrity could favour better long-term UF rates [14 , 16]. Our results also support 
previous reports indicating no apparent impact of the type of solution on plasma cytokine levels 
[17 , 18] ( Table 2 ).  
 
Hormonal disturbances of appetite regulation in PD patients have been a subject of attention in 
the last years. Reported abnormalities include hyperleptinaemia [19] and hyperadiponectinaemia 
[20 , 21], high plasma levels of total, but not the active acylated fraction of ghrelin [22], YY 
peptide [23] and cholecystokinin [24], as also more or less markedly disturbed patterns of 
secretion of gut peptides following meals [11 , 23 , 25 , 26 , 27]. The compared effects of different 
PD solutions on the secretion patterns and plasma levels of these hormones have been 
insufficiently studied. Plasma leptin levels are significantly higher in PD than in haemodialysis 
patients, a difference that persists after controlling for fat mass [28]. This phenomenon has been 
attributed to the capacity of glucose to stimulate directly secretion of leptin by peritoneal 
adipocytes [29]. In the clinical setting, the short-term effect of glucose-based dialysate on plasma 
leptin levels is a matter of controversy [11 , 29]. Partial substitution of glucose-based by 
icodextrin-based PD solutions results in lower plasma levels of leptin and insulin and higher 
plasma levels of adiponectin [12]. On the other hand, hypertonic (3.86%) glucose-based dialysate 
is able to inhibit partially acute ghrelin [11], but not PYY secretion [23]. Finally, PD is able to 
dialyze adipokines and gut peptides [30 , 31], but it is unclear if this factor has any significant 
influence on the plasma levels or the physiology of these hormones.  
 
There is a remarkable paucity of information about the potential effects of so-called 
biocompatible PD solutions on the secretion patterns and plasma levels of adipokines and gut 
appetite-regulatory peptides. These solutions appear to induce leptin secretion by cultured 
adipocytes to a higher extent than classic lactate-based solutions [32], but the clinical significance 
of this finding is unknown. Trials comparing classic and new solutions in the clinical setting have 
not addressed this question, and only some controversial results on selected cytokine levels have 
been reported [17 , 18].  
 
Our results show no apparent effect of BL solutions over L solutions for the majority of the 
hormones scrutinized ( Table 4 ). Interestingly, we observed significantly higher plasma levels of 
acyl ghrelin during treatment with BL solutions. This pattern, combined with similar plasma levels 
of anorexigenic peptides, could configurate a more orexigenic scenery than L solutions, 
contributing to explain the results of previous reports, suggesting that biocompatible solutions may 
bear a less negative effect on appetite than L solutions [33 , 34]. Acyl ghrelin may also stimulate 
GH secretion [35], which may help to understand the higher plasma levels of GH observed during 
the BL phase ( Table 4 ). We do not have a clear explanation for the different levels of acyl-ghrelin 
observed during the study phases, mainly because there is a remarkable lack of information on the 
factors that regulate the physiology of this hormone in patients with chronic kidney disease. The 
particular conditions favoured by BL over L solutions (acid–base status, less GDP content, lower 
lactate load) could potentially modify the secretion patterns of this hormone. The presence of 
similar levels of total ghrelin in both phases, with a close to significant increase in the acyl-
ghrelin/total ghrelin ratio ( Table 4 ), could also be consistent with a longer half-life of acylated 
ghrelin under BL solutions. On the other hand, we found moderately, but significantly, higher 
plasma levels of adiponectin during treatment with BL solutions than with L solutions. This 
phenomenon could follow an improvement of the acid–base status brought by BL solutions 
because metabolic acidosis has been shown to lower circulating adiponectin levels through 
inhibition of adiponectin gene transcription in adipocytes [36]. However, the clinical significance 
of this finding is unclear because the differences observed were small. Moreover, adiponectinemia 
does not have a clear clinical interpretation in patients with chronic kidney disease. This adipokine 
appears to have antiinflammatory and antiatherogenic properties [20], but some studies have even 
observed an inverse correlation between plasma levels of adiponectin and survival, in these 
patients [21].  
 
The main strength of this study is a rigorous and comprehensive design, permitting clear 
comparisons between phases. The relatively short follow-up may have limited the significance of 
the findings but permitted stable conditions (prescription, clinical events …), which are difficult to 
sustain in long-term PD. A second limitation is the lack of dynamic studies, including meal 
provocation tests, which could have contributed to clarify the potential effects of PD solutions on 
the physiology of these hormones. More importantly, we did not search for potential variations in 
appetite scores. The latter could have disclosed clinical correlates of the differences between the 
hormonal patterns observed during the study phases. 
 
In summary, this short-term randomized crossover study, performed under strictly controlled 
conditions, shows that, when compared with classic L solutions, newer BL solutions associate 
higher plasma levels of acyl-ghrelin, adiponectin and growth hormone. The potential contribution 
of these differences to the improved appetite scores and survival rates reported after the use of 
these solutions will need to be assessed in future studies. 
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